Alivus Life Sciences incorporates wholly owned subsidiary in Brazil
- Alivus Life Sciences incorporated wholly owned subsidiary Alivus Life Sciences Do Brasil Ltda in Brazil
- Entity registered in Sao Paulo on September 15, 2026 with authorized capital of R$ 500,000
- Company holds 100% stake via cash consideration not exceeding R$ 500,000
- Transaction approved by Brazilian National Registrar of Legal Entities
*this image is generated using AI for illustrative purposes only.
Alivus Life Sciences Limited incorporated a wholly owned subsidiary, Alivus Life Sciences Do Brasil Ltda, in the State of Sao Paulo, Brazil. The registration took place on September 15, 2026.
The company disclosed the incorporation pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also referenced SEBI circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.
Subsidiary Details
The new entity operates within the pharmaceuticals sector. Alivus Life Sciences will hold 100% of the paid-up share capital. The transaction involved a cash consideration of up to R$ 500,000.00.
| Particulars | Details |
|---|---|
| Name | Alivus Life Sciences Do Brasil Ltda |
| Country | Brazil |
| Authorized Capital | R$ 500,000.00 |
| Shareholding | 100% |
| Regulatory Approval | Federative Republic of Brazil National Registrar of Legal Entities |
The promoter group and group companies have no interest in the entity. The transaction does not fall under related party transactions. As this is a newly incorporated company, turnover and size metrics are not applicable.
Historical Stock Returns for Alivus Life Sciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.81% | +0.01% | -1.05% | +45.22% | +47.45% | +92.66% |
What specific pharmaceutical products or therapeutic areas will Alivus Life Sciences prioritize for entry into the Brazilian market?
How does this expansion into Brazil align with Alivus's broader international growth strategy and revenue targets for the next fiscal year?
What are the anticipated regulatory timelines for obtaining necessary approvals from ANVISA to commence commercial operations in Brazil?
20
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
